De‐escalating radical surgery for select FIGO Stage I cervical cancer Authors: Sara Moufarrij, Rene Pareja, Angélica Fletcher, Sarikapan Wilailak, Nadeem R Abu‐Rustum, the FIGO Committee on Women's Cancer Published: 2026 ABSTRACT AbstractFour recent prospective trials demonstrated that de‐escalation of radical surgery for select patients with apparent low‐risk, FIGO Stage I cervical cancer does not compromise cancer‐related survival but does improve quality of life and provide the opportunity to preserve fertility. We present a critical review of ConCerv, SHAPE, GOG‐278, and LESSER, which have set the stage for de‐escalation of surgery for low‐risk, early‐stage cervical cancer. ConCerv, a prospective phase II study evaluating the feasibility and oncologic outcomes of conization alone or simple hysterectomy in patients with early‐stage cervical carcinoma, found a low recurrence rate of 2.4% in patients who underwent a cone biopsy with lymph node assessment and 0% in those who underwent simple hysterectomy with lymph node evaluation. SHAPE, a phase III trial assessing the safety of simple hysterectomy compared to radical hysterectomy in this patient population, showed no difference in pelvic recurrences between both groups. GOG‐278, an international cohort study evaluating the efficacy of cone biopsy versus simple hysterectomy with pelvic nodal assessment, found a 3‐year recurrence‐free survival rate of 94.8% in the cone biopsy group, with no recurrences noted in the simple hysterectomy group. Finally, LESSER, a phase II proof‐of‐concept trial studying cancer and quality‐of‐life outcomes in patients who underwent either a simple or modified radical hysterectomy for early‐stage cervical cancer, found no difference in the disease‐free survival rate or overall survival between both groups. Rates of postoperative complications were also similar in both arms. Based on these trials, we propose the following set of criteria for which de‐escalation of surgical intervention would be appropriate for select Stage I disease: tumors ≤2 cm on cone biopsy; magnetic resonance imaging showing <50% of cervical stromal invasion with no evidence of metastasis; and a histology of either squamous cell carcinoma of any grade or either grade 1 or 2 adenocarcinoma, with depth of invasion <10 mm and no lymphovascular invasion.Keywords: cervical cancer, fertility preservation, radical hysterectomy, surgical de‐escalation INTRODUCTION Cervical cancer is the fourth most common cancer in women worldwide. 1 Patients with cervical cancer often have difficulty reconciling their fertility goals and sexual health with the impact and adverse effects of surgical treatment. Radical hysterectomy has been the standard surgical management for early‐stage cervical cancer and has been associated with excellent survival; however, it is associated with potential toxicities. These include blood loss, short‐ and long‐term bowel and bladder dysfunction, loss of fertility, sexual dysfunction, as well as lymphedema. 2 , 3 , 4 , 5 Furthermore, the morbidity of radical hysterectomy is directly proportional to the degree of radicality, especially the extent of paracervical resection. This is due to the compromise of autonomic fibers of the inferior hypogastric plexus and pelvic splanchnic nerves. 6 The need for parametrectomy in selected patients with early‐stage cervical cancer had long been questioned. In a study by Covens et al. 7 that evaluated the incidence of parametrial involvement in patients with FIGO Stage IA1–IB1 cervical cancer with tumors ≤2 cm, depth of invasion (DOI) <10 mm, and negative pelvic lymph nodes, disease involving the parametrium was found only in 0.6% of cases, with a relapse rate at 5 years of 4%. Similarly, Wright et al. 8 found an incidence rate of parametrial disease in only 0.4% of patients with negative pelvic nodes, absence of lymphovascular space invasion (LVSI), and tumors <2 cm. Given the associated morbidity of radical hysterectomy with apparent minimal cancer‐related benefit, less radical surgical approaches have been increasingly considered. We present a review of retrospective studies that have laid the framework for de‐escalating radical surgery for early‐stage cervical cancer. We also discuss four landmark prospective trials—ConCerv, SHAPE, GOG‐278, and LESSER—which have changed the paradigm of surgical management of this disease. Finally, we propose criteria for patient selection for de‐escalation, which we believe, if adapted universally, will allow for appropriate patients to pursue fertility‐sparing interventions. This will also decrease the radicality of surgical procedures, thus reducing the risk of postoperative morbidity and improve quality of life. DE‐ESCALATING RADICAL SURGERY FOR CERVICAL CANCER: A SUMMARY OF RETROSPECTIVE DATA Several retrospective studies have sought to address the need for radical hysterectomy in early‐stage cervical cancer. Sia et al. 9 compared outcomes between patients with FIGO Stage IA2 or IB1 cervical cancer <2 cm who underwent simple and radical hysterectomies using data from the National Cancer Database. They reported no association between surgical radicality and survival for women with Stage IA2 tumors (hazard ratio 0.70; 95% CI, 0.41–1.2; 5‐year survival rate 95.1% for radical hysterectomy and 97.6% for simple hysterectomy). 9 Interestingly, they found a 55% increase in all‐cause mortality for women with Stage IB1 cervical cancer who underwent simple compared with radical hysterectomy; however, when adjusting for nodal assessment, the difference in survival was no longer statistically significant. Wu et al. 10 published a meta‐analysis of 21 studies of patients with cervical cancer, noting that those with FIGO 2009 Stage IB1 malignancies had a higher recurrence rate after simple hysterectomy compared to patients with Stage IA2 disease (7% vs. 2.7%). However, it is important to note that only 3% of the cases had tumors <2 cm in size, and most recurrences in the IB1 group occurred in cases with high‐risk disease, which, in part, could have driven the results. Furthermore, only 71.8% of patients had full lymph node assessment, deviating from the recommended standard of care and raising the possibility of unknown occult nodal disease. 10 Therefore, upon critical review, these studies suggest that simple hysterectomy, in select cases, provides the same oncologic outcomes when proper lymph node evaluation is conducted. As previously mentioned, pelvic lymph node assessment in early‐stage cervical cancer remains a cornerstone of surgical management. Several studies have shown that pelvic lymph node metastasis is a significant risk factor for survival in patients with cervical cancer. 11 Hence, lymph nodes should be assessed in all patients with early‐stage cervical cancer, except in cases with Stage IA1 disease without LVSI, given the low risk of nodal disease in this patient population. 12 Complete pelvic lymphadenectomy, however, is associated with short‐ and long‐term morbidities, including blood loss, infection, nerve and vascular injury, lymphedema, and venous thromboembolism. 13 , 14 , 15 To decrease complications from such a procedure and improve the detection of micrometastatic disease, sentinel lymph node mapping techniques were developed, and various studies have validated the diagnostic accuracy of sentinel lymph node biopsy in this cancer type. 16 , 17 , 18 , 19 A recently published multicenter, randomized, noninferiority trial, which assessed the effect of sentinel lymph node biopsy on survival in patients with early‐stage cervical cancer with tumors up to 3 cm, found no difference in 3‐year cancer‐specific survival in patients who underwent sentinel lymph node biopsy compared to those who had a total pelvic lymphadenectomy after sentinel node evaluation. 20 Thus, sentinel lymph node evaluation is a critical and safe procedure and therefore should be part of surgical assessments for patients with clinical Stage I cervical cancer. De‐escalation surgery can be offered to a select patient population when accurate pelvic lymph node assessment has been performed. Tseng et al. 21 solidified the safety of uterine‐preserving surgery with nodal assessment in patients with FIGO 2009 Stage IB1 cervical cancer in the group's Surveillance, Epidemiology, and End Results (SEER) database retrospective study. They evaluated 2717 patients with FIGO 2009 Stage IB1 cervical cancer who underwent pelvic lymphadenectomy, comparing conization (n = 36), trachelectomy (n = 89), and simple hysterectomies (n = 682) with (modified) radical hysterectomies (n = 1764); they found no difference in 10‐year disease‐specific survival rate between the two groups (93.5% vs. 92.3%; P = 0.511). 21 Additional retrospective studies by Palaia et al. 22 and Biliatis et al. 23 demonstrated the safety of fertility preservation for Stage IB cervical cancer. Palaia et al. 22 prospectively identified patients with Stage IA2–IB1 cervical cancer with tumors <2 cm, absence of LVSI, and without overt nodal metastasis on imaging. Patients underwent laparoscopic pelvic lymphadenectomy and vaginal trachelectomy. Among the 14 patients enrolled, the median tumor size was 17 mm and the most common histotype was squamous cell carcinoma (11 of 14, 79%). 22 No recurrences were observed in the follow‐up period, and three patients had a term delivery of the eight who conceived. Biliatis et al. 23 similarly assessed survival and obstetric outcomes after conservative surgery in patients with Stage IB1 disease. Sixty‐two patients were identified, 35 (56.4%) who had been treated with loop biopsy and 27 (45.6%) with simple hysterectomy; 57 (92%) underwent pelvic lymphadenectomy. The median follow‐up was 56 months (range, 16–132), with no deaths or recurrences found, and seven full‐term pregnancies achieved. These studies set the stage for investigating de‐escalation in surgery for early‐stage cervical cancer. PROSPECTIVE TRIALS THAT CHANGED THE LANDSCAPE OF SURGICAL INTERVENTION FOR FIGO STAGE I CERVICAL CANCER The compelling retrospective data highlighting increased morbidity and questionable oncologic benefit with radical surgery over less radical surgery for highly selected Stage I cases of cervical cancer laid the groundwork for four prospective trials. These four trials assessed oncologic outcomes and quality‐of‐life metrics in patients who underwent less radical surgery for Stage I cervical cancer. ConCerv, a prospective, phase II, single‐arm, multicenter study, evaluated feasibility and oncologic outcomes of conization alone or simple hysterectomy in patients with early‐stage cervical carcinoma. 24 All patients underwent diagnostic excision with conization before enrollment. Eligible patients were deemed to have low‐risk cervical cancer if they had tumors with FIGO 2009 Stage IA2–IB1 cervical squamous (any grade) or adenocarcinoma (grade 1 or 2) histology; tumor size ≤2 cm by physical examination or imaging; no LVSI; negative imaging for metastatic disease as assessed by computed tomography, magnetic resonance imaging (MRI), or positron emission tomography scan; DOI ≤10 mm; and negative conization margins and endocervical curettage (Table 1). Patients who desired fertility preservation underwent a second surgery for lymph node evaluation with either full pelvic lymph node dissection or sentinel lymph node biopsy. Those who did not desire fertility preservation underwent a simple hysterectomy with pelvic lymph node assessment. TABLE 1Inclusion criteria for the ConCerv, SHAPE, GOG‐278, and LESSER clinical trials.ConCervSHAPEGOG‐278LESSERStage, tumor sizeFIGO 2009 Stage IA2–IB1, tumor size ≤2 cmFIGO 2009 Stage IA2–IB1, tumor size ≤2 cmFIGO 2009 Stage IA1 with LVSI–IB1, tumor size ≤2 cmFIGO 2009 Stage IA2–IB1, tumor size ≤2 cmHistologySquamous cell (any grade) or usual type adenocarcinoma (grade 1 or 2 only)Any grade squamous cell, adenocarcinoma, or adenosquamous carcinomaAny grade squamous, adenocarcinoma, or adenosquamous carcinomaAny grade squamous cell, adenocarcinoma, or adenosquamous carcinomaLVSINoYesYesYesDOI≤10 mm on LEEP or cone biopsy<10 mm on LEEP, cone biopsy, or by preoperative pelvic MRI showing invasion <50% in cervical stroma≤10 mm on LEEP, cone biopsyNot explicitly mentionedCone mandated?Yes, with negative margins (latter defined as no invasive cancer within 1 mm of both endocervical and ectocervical margins and no adenocarcinoma in situ, CIN 2 or 3 at inked or cauterized margin). One repeat conization was permittedNoYes, with negative margins (defined as no invasive cancer or dysplasia on lateral or endocervical margins). A second conization to achieve negative margins was permittedNoImaging required to rule out metastatic disease?YesYesYesNoAbbreviations: CIN, cervical intraepithelial neoplasia; DOI, depth of invasion; LEEP, loop electrosurgical excision procedure; LVSI, lymphovascular space invasion; MRI, magnetic resonance imaging. Inclusion criteria for the ConCerv, SHAPE, GOG‐278, and LESSER clinical trials. Abbreviations: CIN, cervical intraepithelial neoplasia; DOI, depth of invasion; LEEP, loop electrosurgical excision procedure; LVSI, lymphovascular space invasion; MRI, magnetic resonance imaging. Among the 100 patients enrolled, 44 had cervical conization with lymph node assessment and 40 had cone biopsy followed by simple hysterectomy with lymph node evaluation. Residual disease in a post‐conization hysterectomy was found only in 1 of 40 patients, which equates to a failure rate of 2.5%. Three patients recurred within 2 years of surgery for a cumulative incidence rate of 3.5%, with a recurrence rate of 2.4% (1 of 42) in patients who underwent a cone biopsy with lymph node assessment and 0% (0 of 36) in those who underwent simple hysterectomy with lymph node assessment. Although the study is limited by its prolonged trial period and inconsistent lymph node assessments at the various sites, it was monumental in demonstrating that conservative surgery with cold knife conization or simple hysterectomy with nodal assessment for appropriately selected patients is an effective treatment option. Furthermore, ConCerv highlighted the importance of conization in ensuring appropriate selection of cases and in predicting no residual disease in the final hysterectomy specimen. In addition, it further emphasized the importance of nodal assessment even in early‐stage cervical cancer, as 5% of patients had positive pelvic nodes. The second landmark study to evaluate de‐escalation of surgery for early‐stage cervical cancer was the SHAPE trial—a phase III, international, randomized trial assessing the safety of simple hysterectomy compared to radical hysterectomy. Similarly to ConCerv, patients were eligible if they had FIGO 2009 Stage IA2–IB1 squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix; however, unlike ConCerv, the histopathology could be of any grade and LVSI was permitted (Table 1). 25 The lesions were similarly limited to a maximum size of 2 cm and DOI of 10 mm on loop electrosurgical excision procedure (LEEP) or cone biopsy or with MRI showing invasion <50% of cervical stromal tissue, with no evidence of distant disease or lymph node metastasis on preoperative imaging. Patients underwent 1:1 randomization to undergo pelvic lymph node assessment with either simple hysterectomy or Type II radical hysterectomy. Overall, 700 patients (350 in each group) were included in the study, with most having Stage IB1 disease (91.7%) and grade 1 or 2 pathology (59.3%). A diagnostic LEEP or cone biopsy was performed in 80% of patients. Eleven pelvic recurrences occurred in the simple hysterectomy group and 10 in the radical hysterectomy group, with an incidence rate of pelvic recurrence at 3 years of 2.5% in the simple hysterectomy group and 2.17% in the radical hysterectomy group, demonstrating noninferiority for less radical surgery. Intraoperative surgical complications occurred in 24 (7.1%) of 338 patients who had a simple hysterectomy compared with 22 (6.4%) of 344 patients who had a radical hysterectomy. Additionally, the radical hysterectomy group showed a higher incidence of urinary retention compared to the simple hysterectomy group (11% vs. 0.6%, P < 0.001) as well as urinary incontinence (5.5% vs. 2.4%, P = 0.048) within 4 weeks of surgery, with these differences remaining significant beyond the 4‐week period. Furthermore, pelvic pain in the first month was more common in the radical hysterectomy group compared to the patients who underwent a simple hysterectomy (5.6% vs. 2.6%, P = 0.05). Quality‐of‐life and sexual function measures favored patients who underwent simple hysterectomy versus radical hysterectomy. Although the recurrence rate is consistent with the results from the ConCerv trial, it is important to note that SHAPE included patients with grade 3 adenocarcinoma (2.7% of the study population), tumors with LVSI (13.4%), and residual disease in the hysterectomy specimen (45.8%). Given these small numbers, more data are needed to determine whether SHAPE inclusion criteria (such as presence of LVSI and grade 3 adenocarcinomas) can be used. Although this trial helped reinforce the findings from ConCerv, it is important to note its limitations; mainly, the trial was conducted in Canada, Western Europe, and South Korea, with poor representation from low‐ and middle‐income countries. Nevertheless, the findings poignantly demonstrate the safety and efficacy of simple hysterectomy with pelvic lymphadenectomy for early‐stage cervical cancer with low‐risk features. The third landmark study is GOG‐278, an international cohort study of patients with FIGO 2009 Stage IA1 with LVSI, IA2, or IB1 carcinoma of the cervix that evaluated the efficacy and morbidity of nonradical surgery. Patients were stratified by fertility preservation (with cone biopsy) or simple hysterectomy with pelvic nodal assessment. Similarly to SHAPE, GOG‐278 included tumors ≤2 cm of any grade, DOI ≤10 mm, and no evidence of metastasis on preoperative imaging (Table 1). 26 Similarly to ConCerv, patients must have had cone biopsy or LEEP prior to study entry. A total of 224 patients enrolled, with 72 (32%) choosing fertility preservation and 152 (68%) choosing hysterectomy. Forty‐seven percent of the tumors were Stage IA1 with LVSI and 63% were of squamous histology. Among 31 patients who wanted to preserve fertility, 16 pregnancies in 15 patients occurred, with 4 spontaneous abortions, 3 preterm deliveries, and 9 full‐term deliveries. Interestingly, the premature delivery rate observed in GOG‐278 was higher than ConCerv (25% [95% CI, 5–57%] vs. 7% [95% CI, 0–34%]). The median follow‐up was 37 months. Three patients (4%) in the cone biopsy group recurred in the cervix, for a 3‐year recurrence‐free survival rate of 94.8% (95% CI, 89–100%), whereas no recurrences were noted in the simple hysterectomy group. Bladder and bowel function as well as sexual function decreased initially but recovered over time in both groups. 27 The final landmark study is the LESSER trial, a phase II, proof‐of‐concept trial that assessed cancer outcomes and quality‐of‐life metrics in patients who underwent either a simple or modified radical hysterectomy for FIGO 2009 Stage IA2–IB1 cervical cancer. Patients were included if they had known adenocarcinoma, squamous, or adenosquamous cancer of the cervix diagnosed by LEEP, cone or cervical biopsy, as well as tumors ≤2 cm, similarly to GOG‐278 and ConCerv. Interestingly, there were no restrictions for DOI or LVSI. The 40 patients included were randomized to simple or modified radical hysterectomy, both with pelvic lymph node dissection. The disease‐free survival rate was the same in both groups 95% [95% CI, 68–99%] after simple hysterectomy and 100% after modified radical hysterectomy (no disease‐free survival events were observed in 20 patients, P = 0.30). 27 The 5‐year overall survival rates were also similar (90% vs. 91%, respectively, P = 0.46). Rates of postoperative complications of any grade were similar in both arms (3 of 20 patients [15%] in the simple hysterectomy group; 5 of 20 patients [25%] in the modified radical hysterectomy group). 28 No major differences in quality of life were found over time or between the two surgical groups. Nine patients (22.5%) had tumors with LVSI, a higher percentage than those included in the SHAPE trial, and only 12 patients (30%) had DOI >1 cm, although 27.5% of patients did not have reported DOI. WHAT WORKUP IS NEEDED TO DETERMINE CANDIDATES FOR DE‐ESCALATION? Considering these recent prospective study findings, de‐escalation surgery for select cases of Stage I cervical cancer should be considered. It is crucial, however, that appropriate workup is undertaken to carefully select patients with low‐risk cervical cancer to ensure good outcomes. In other words, preoperative assessment must be escalated and include multidisciplinary review to determine appropriate candidates for less radical surgery. A pelvic MRI is usually needed for preoperative evaluation, especially if planning definitive treatment with conization, trachelectomy, or a simple hysterectomy. Furthermore, a cervical conization specimen (preferably nonfragmented) with thorough pathology review is important because it provides the most accurate method of determining histology, grade, tumor size, LVSI, DOI, and margin status. The International Society of Gynecologic Pathology recommends that DOI should be reported as the deepest invasion of any single specimen for final staging. 29 Although the SHAPE, GOG‐278, and LESSER trials did not exclude cases with LVSI, about 87% of patients in the SHAPE study and 67.5% in the LESSER trial did not have LVSI, whereas this information is unknown for GOG‐278. Given that it was a known exclusion criterion in ConCerv, and that LVSI has been proven to increase the risk of nodal metastasis, the most conservative inclusion criteria would exclude such cases. Proper assessment of histology is crucial, especially since ConCerv only included squamous cell and adenocarcinoma histologies, and only SHAPE and GOG‐278 included adenosquamous histology; however, only 3.3% of the study population in SHAPE and 5% in GOG‐278 had adenosquamous histology, but none were in the conization‐only group. No cases of adenosquamous histology were reported in the LESSER study. Even within the human papillomavirus‐associated adenocarcinoma group, grade 3 histology was only marginally represented in the SHAPE trial (2.7%), and it was not reported in either GOG‐0278 or the LESSER study. Thus, it is difficult to conclude whether this group will have the same outcomes as its lower‐grade counterparts. Importantly, treatment cannot be abbreviated for other less common histologies, such as small cell neuroendocrine, gastric‐type adenocarcinoma, mesonephric adenocarcinoma, mucinous type, and clear cell, given that not all the studies included patients with these histologies. WHO IS A GOOD CANDIDATE FOR DE‐ESCALATION SURGERY? Based on the results discussed above, we propose criteria for patients with Stage I cervical cancer who may be eligible for conservative surgery, whether through a fertility‐sparing approach or simple total hysterectomy (Box 1, Figure 1). These patients should undergo a cone biopsy with negative margins, have tumors ≤2 cm, and undergo an MRI showing <50% of cervical stromal invasion and no evidence of metastasis. Of note, the MRI should assist in determining whether a cone biopsy is needed for further workup but should not replace it. In other words, if there is evidence of >50% stromal invasion but no obvious large tumor on physical exam, a conization is still appropriate. If patients have already undergone a conization, it is reasonable to defer repeat conization if the margins were negative and the specimen intact. The tumor should be either squamous cell carcinoma of any grade or either grade 1 or 2 adenocarcinoma, with DOI <10 mm and no LVSI. We would caution against de‐escalation for patients with visible tumors who have not undergone cone biopsy given the discrepancy between clinical and pathologic staging for cervical cancer. 30 , 31 Conservative surgery criteria (i.e. safest selection criteria to treat with conization or simple hysterectomy plus pelvic lymph node assessment) for Stage I cervical cancer. Criteria Cone biopsy with negative margins for invasive cancer or CIN 2–3 or ACIS (preferred)No LVSI (preferred)DOI <10 mm on cone biopsyMRI showing <50% cervical stromal invasion and no metastasisSquamous carcinoma of any grade, or grade 1 or grade 2 usual type adenocarcinoma (preferred)Tumor size ≤2 cm confirmed on pathologic assessment of cone biopsy Abbreviations: ACIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; DOI, depth of invasion; LVSI, lymphovascular space invasion; MRI, magnetic resonance imaging. Flow chart for determining candidacy for de‐escalation surgery for presumed early‐stage, low‐risk cervical cancer. LVSI, lymphovascular space invasion; DOI, depth of invasion; G, grade; MRI, magnetic resonance imaging. Although the evidence supporting conservative surgery for early‐stage cervical cancer is strong, it is important to assess the feasibility of the workup required for de‐escalation given that low‐ to middle‐income countries have a disproportionately higher incidence of cervical cancer. Although pelvic MRI is routinely used to determine tumor size, stromal invasion, and margin status, thorough and expert clinical examination, transvaginal ultrasound, and careful pathology review of a cone or LEEP specimen may serve as alternatives where MRI is limited. Furthermore, sentinel lymph node mapping may also be difficult to implement due to equipment and tracer requirements, making selective pelvic lymphadenectomy a more practical option at this time. Nevertheless, conservative procedures such as conization or simple hysterectomy may reduce operative morbidity, hospital stay, and resource utilization, supporting their potential feasibility in resource‐limited health systems. CONCLUSION Given the low risk of local disease spread and recurrence in early‐stage cervical cancer, surgical de‐escalation should be considered for patients who meet appropriate criteria. Conservative surgery in the appropriate patient can allow for fertility goals to be met without compromising oncologic outcomes while reducing the risk of adverse effects from radical surgery. Based on four landmark prospective trials addressing de‐escalation for early‐stage cervical cancer, we propose a set of criteria to guide gynecologic oncologists in counseling their patients for conservative surgery. In line with the World Health Organization's global strategy for the elimination of cervical cancer as a public health concern, we believe that preinvasive or early‐stage invasive cervical lesions can be treated and cured without compromising quality of life, fertility goals, or sexual function. We hope these criteria can be standardized on a global scale and provide less invasive surgical opportunities for patients with early‐stage disease. AUTHOR CONTRIBUTIONS Sara Moufarrij: conceptualization and writing original draft; Rene Pareja: writing, review, and editing; Angélica Fletcher: writing, review, and editing; Sarikapan Wilailak: writing, review, and editing; Nadeem R. Abu‐Rustum: Conceptualization and writing original draft. FUNDING INFORMATION The authors have nothing to report. CONFLICT OF INTEREST STATEMENT N.R. Abu‐Rustum reports research funding from GRAIL paid to the institution. Other authors have nothing to disclose. DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created or analyzed in this study. REFERENCES Associated Data Data Availability Statement Data sharing is not applicable to this article as no new data were created or analyzed in this study.